| Pharmaceutical Information |
| Drug Name |
Elosulfase alfa |
| Drug ID |
BADD_D00758 |
| Description |
Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. |
| Indications and Usage |
Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AB12 |
| DrugBank ID |
DB09051
|
| KEGG ID |
D10333
|
| MeSH ID |
C102295
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0J1UA
|
| NDC Product Code |
68135-100; 71931-500 |
| UNII |
ODJ69JZG85
|
| Synonyms |
GALNS protein, human | N-acetylgalactosamine-6-sulfatase, human | mucopolysaccharidosis type IVA protein, human | galactose-6-sulfate sulfatase, human | GALNAC6S protein, human | Morquio syndrome protein, human | galactosamine (N-acetyl)-6-sulfate sulfatase, human | Vimizim | elosulfase alfa | BMN-100 | BMN 110 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
9025-60-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
